clinical trial · NCT06838195
Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd·phase3·active not recruiting·n = 8,000
DysenteryDysentery, ShigellaS. Flexneri-S. Sonnei bivalent conjugate vaccinePlacebo
brief summary
The goal of this clinical trial is to evaluate the protective efficacy of S. Flexneri-S. Sonnei bivalent conjugate vaccine against diarrhea caused by Shigella infection in infants and children aged 6 months to 5 years. Researchers will observe the incidence of diarrhea of any severity due to Shigella flexneri and Shigella sonnei infection 30 days after full immunization. The subjects will receive 2 doses of vaccination.
started
May 12, 2025
primary completion
Jul 2, 2028
completion
Jul 30, 2028
last updated
Apr 1, 2026
official title
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating the Protective Efficacy, Immunogenicity, and Safety of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine in Infants and Children Aged 6 Months to 5 Years in Bangladesh
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol